Eskişehir Osmangazi University, School of Medicine, Division of Rheumatology, Eskisehir, Turkey.
2012 Vol.30, N°3 ,Suppl.72 - PI 0104, PF 0107
Free to view (click on article PDF icon to read the article)
The frequency of FMF-related amyloidosis has been decreased by colchicine use over the past few decades. However, the beneficial effect of colchicine may differ in accordance with nephropathic stages. When used in proper doses and with compliance, colchicine is very effective in preclinical and proteinuric stages of FMF-related amyloidosis. Even so, a large number of patients with nephrotic range proteinuria, despite compliance and an ideal dose of colchicine, may still progress to end-stage renal failure (ESRF).We do not know exactly what we can do with such patients. This paper discusses the therapeutic approach to patients with FMF-related amyloidosis.
PMID: 23010471 [PubMed]
Received: 25/07/2012 - Accepted : 30/08/2012 - In Press: 25/09/2012 - Published: 19/11/2012